A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

Not specified

Study Completion Date

February 29, 2000

Conditions
HIV Infections
Interventions
DRUG

Zidovudine

DRUG

Didanosine

Trial Locations (22)

10003

Beth Israel Med Ctr, New York

10016

Bellevue Hosp / New York Univ Med Ctr, New York

10465

Jack Weiler Hosp / Bronx Municipal Hosp, The Bronx

14642

Univ of Rochester Medical Center, Rochester

21287

Johns Hopkins Hosp, Baltimore

35294

Univ of Alabama at Birmingham, Birmingham

46202

Methodist Hosp of Indiana / Life Care Clinic, Indianapolis

60611

Northwestern Univ Med School, Chicago

60612

Cook County Hosp, Chicago

Rush Presbyterian - Saint Luke's Med Ctr, Chicago

60640

Louis A Weiss Memorial Hosp, Chicago

80262

Univ of Colorado Health Sciences Ctr, Denver

275997215

Univ of North Carolina, Chapel Hill

331361013

Univ of Miami School of Medicine, Miami

432101228

Ohio State Univ Hosp Clinic, Columbus

452670405

Univ of Cincinnati, Cincinnati

462025250

Indiana Univ Hosp, Indianapolis

606575147

Illinois Masonic Med Ctr, Chicago

941102859

San Francisco Gen Hosp, San Francisco

981224304

Univ of Washington, Seattle

02114

Harvard (Massachusetts Gen Hosp), Boston

02115

Brigham and Women's Hosp, Boston

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Glaxo Wellcome

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000823 - A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection | Biotech Hunter | Biotech Hunter